NCT04934124View on ClinicalTrials.gov

Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ITI 333 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

December 23, 2020

Primary Completion Date

August 23, 2021

Study Completion Date

August 23, 2021

Conditions
Healthy Volunteers
Interventions
DRUG

ITI-333

ITI-333 oral solution

OTHER

Placebo

Matching placebo

Trial Locations (1)

07724

Clinical Site, Eatontown

Sponsors
All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

Intra-Cellular Therapies, Inc.

INDUSTRY